Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report

Overview of attention for article published in BMC Cancer, January 2018

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (71st percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

So far, Altmetric has seen 144 X posts from 7 X users, with an upper bound of 14,024 followers.

Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report https://t.co/2AQZ903n24

Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report https://t.co/2AQZ903n24

Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report https://t.co/2AQZ903n24

Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report https://t.co/2AQZ903n24

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 140 additional X posts.